Impact Biomedical (IBO) Income from Continuing Operations (2022 - 2026)
Impact Biomedical (IBO) posted Income from Continuing Operations of 2284000.0 for Q1 2026, down 54.85% on a QoQ basis from 1475000.0 in Q3 2025, and down 78.72% year-over-year from 10731441.18 in Q1 2025.
Impact Biomedical (IBO) Income from Continuing Operations (2022 - 2026) Analysis & Trends
Impact Biomedical's Income from Continuing Operations history runs 5 years deep, the most recent figure standing at 2284000.0 for Q1 2026.
- Quarterly Income from Continuing Operations fell 78.72% year-over-year to 2284000.0 in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 19389000.0 (up 22.51% YoY) and the FY2024 annual result came in at 24770000.0, down 462.06% from the prior year.
- Income from Continuing Operations was 2284000.0 for Q1 2026 at Impact Biomedical, down from 1475000.0 in the prior quarter.
- Across five years, Income from Continuing Operations topped out at 4241000.0 in Q3 2024 and bottomed at 27100000.0 in Q4 2024.
- A 5-year average of 3662600.0 and a median of 1261000.0 in 2023 frame the typical range for Income from Continuing Operations.
- Peak annual rise in Income from Continuing Operations reached 460.32% in 2024, while the deepest fall reached 2049.09% in 2024.
- Impact Biomedical's Income from Continuing Operations stood at 3366000.0 in 2022, then soared by 62.54% to 1261000.0 in 2023, then tumbled by 2049.09% to 27100000.0 in 2024, then surged by 94.56% to 1475000.0 in 2025, then tumbled by 54.85% to 2284000.0 in 2026.
- Business Quant data shows IBO's Income from Continuing Operations at 2284000.0 in Q1 2026, 1475000.0 in Q3 2025, and 14352000.0 in Q2 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Income (Continuing) (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | -37.09 Mn |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 227.36 Mn |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | -3.68 Mn |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 1.03 Bn |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 727.20 Mn |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | -26.94 Mn |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 362.00 Mn |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | -453.82 Mn |
| 10 | Impact Biomedical | 47.44 Mn | 50.67 Mn | - | -2.28 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -2.28 Mn |
| Sep 30, 2025 | -1.48 Mn |
| Jun 30, 2025 | -14.35 Mn |
| Mar 31, 2025 | -1.28 Mn |
| Dec 31, 2024 | -27.10 Mn |
| Sep 30, 2024 | 4.24 Mn |
| Jun 30, 2024 | -884,000.00 |
| Mar 31, 2024 | -998,000.00 |
| Dec 31, 2023 | -1.26 Mn |
| Sep 30, 2023 | -1.18 Mn |
| Jun 30, 2023 | -1.12 Mn |
| Mar 31, 2023 | -849,000.00 |
| Dec 31, 2022 | -3.37 Mn |
| Sep 30, 2022 | -2.24 Mn |
| Jun 30, 2022 | -799,000.00 |